• Publications
  • Influence
Dabigatran versus warfarin in patients with atrial fibrillation.
BACKGROUND Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.Expand
  • 6,355
  • 231
  • PDF
Cardiac-resynchronization therapy for mild-to-moderate heart failure.
BACKGROUND Cardiac-resynchronization therapy (CRT) benefits patients with left ventricular systolic dysfunction and a wide QRS complex. Most of these patients are candidates for an implantableExpand
  • 1,407
  • 62
  • PDF
Effect of dronedarone on cardiovascular events in atrial fibrillation.
BACKGROUND Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation. METHODS We conducted a multicenter trial to evaluate the use ofExpand
  • 937
  • 59
  • PDF
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
BACKGROUND Patients surviving ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) are at a high risk of death due to a recurrence of arrhythmia. The implantable cardioverterExpand
  • 1,459
  • 57
  • PDF
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
BACKGROUND Implantable cardioverter-defibrillator (ICD) therapy has been shown to improve survival in patients with various heart conditions who are at high risk for ventricular arrhythmias. WhetherExpand
  • 1,323
  • 55
  • PDF
Apixaban in patients with atrial fibrillation.
BACKGROUND Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin KExpand
  • 1,521
  • 50
  • PDF
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
BACKGROUND We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS In this double‐blindExpand
  • 873
  • 38
  • PDF
Newly identified events in the RE-LY trial.
To the Editor: We wish to update our article about the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial (Sept. 17, 2009, issue).1 After the database was locked on August 15,Expand
  • 694
  • 37
  • PDF
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy
Background— Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in theExpand
  • 1,014
  • 32
  • PDF
Subclinical atrial fibrillation and the risk of stroke.
BACKGROUND One quarter of strokes are of unknown cause, and subclinical atrial fibrillation may be a common etiologic factor. Pacemakers can detect subclinical episodes of rapid atrial rate, whichExpand
  • 956
  • 31
  • PDF